Nader Eldika, MD
Pulmonary Disease · Wichita, KSNPI 1033231006
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 439 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations.
Across 439 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Actelion Pharmaceuticals US, Inc.$964
- Boehringer Ingelheim$824
- Sanofi$361
- Genentech USA, Inc.$349
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,93297%
- Education$2313%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 99 | $2,034 |
| AstraZeneca | 83 | $1,808 |
| Actelion Pharmaceuticals US, Inc. | 47 | $964 |
| Boehringer Ingelheim | 28 | $824 |
| Sanofi | 15 | $361 |
| Genentech USA, Inc. | 21 | $349 |
| Regeneron Healthcare Solutions, Inc. | 13 | $348 |
| United Therapeutics Corporation | 14 | $315 |
| Axsome Therapeutics, Inc. | 10 | $217 |
| Grifols USA, LLC | 7 | $174 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $161 |
| Novartis | 9 | $155 |
| Sunovion Pharmaceuticals Inc. | 23 | $142 |
| Mylan Specialty L.p. | 7 | $142 |
| AbbVie | 4 | $133 |
| Johnson & Johnson(2 entities) | 8 | $125 |
| Jazz Pharmaceuticals Inc. | 5 | $123 |
| Amgen | 6 | $105 |
| Advanced Respiratory, Inc | 4 | $86 |
| Sanofi-aventis U.S. LLC | 2 | $75 |
| Viatris Specialty LLC | 3 | $72 |
| Bayer | 3 | $63 |
| Baxter Healthcare | 3 | $55 |
| Verona Pharma, Inc. | 2 | $42 |
| Merck | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Insmed, Inc. | 2 | $33 |
| La Jolla Pharmaceutical Company | 2 | $30 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Resmed Corp | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Electromed, Inc. | 2 | $20 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Pfizer | 1 | $15 |
| Circassia Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,163 in reported general payments places this provider in the 80th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 16 | $489,765 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 571 | $437,495 |
| OpsumitMacitentan | 24 | $302,373 |
| Spiriva RespimatTiotropium Bromide | 284 | $174,731 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 248 | $172,308 |
| Breo ElliptaFluticasone/Vilanterol | 261 | $113,820 |
| Incruse ElliptaUmeclidinium Bromide | 153 | $61,825 |
| Dupixent SyringeDupilumab | 13 | $48,646 |
| Arnuity ElliptaFluticasone Furoate | 132 | $38,041 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 66 | $37,457 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 244 | $33,595 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 49 | $31,950 |
| Advair HfaFluticasone Propion/Salmeterol | 76 | $30,423 |
| SymbicortBudesonide/Formoterol Fumarate | 82 | $22,567 |
| Spiriva HandihalerTiotropium Bromide | 17 | $14,368 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $964 | $792,13740 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta, Anoro Ellipta | $2,034 | $688,6391,183 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $824 | $206,681333 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,808 | $194,875330 claims |
| MerckDulera | $40 | $10,41029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Wichita
- Abdel-Ghanie Abu-SamraWichita$60K
- Victor SalloumWichita$14K
- Ibrahim RaphaelWichita$13K
- Dennis Oyieng'oWichita$9K
- Mark WencelWichita$9K
- John FlesherWichita$7K
- Youssef YammineWichita$6K
- Raid Abu-AwwadWichita$6K
- Maged El-ZeinWichita$4K
- Son TruongWichita$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.